Next generation drugs for chronic diseases
Addressing the needs of an ageing population

Scroll

At Filamon, we are pioneering a bold, science-driven approach to address chronic inflammatory and degenerative diseases – conditions that continue to increasingly impact millions worldwide, particularly as we age. Our focus is on providing the aging global generation with a renewed chance for productive, improved quality of life, and independent living. Through groundbreaking research and technology, we are reshaping what it means to treat age-related chronic diseases.

OUR COMPANY

Our research approach treats chronic inflammatory and degenerative diseases not as isolated conditions, but as interconnected outcomes of widespread inflammation in the body.

From heart disease and arthritis to cancer and dementia, we believe these diseases stem from the same underlying processes. By targeting inflammation at the core, Filamon’s therapies are designed to address multiple conditions, providing powerful treatment options for the aging population who suffer from two or more chronic diseases.

Our Science

The Filamon Difference: Multimodal Therapies for Complex Diseases

The challenge with conventional treatments is that they are monomodal, designed to act on a single pathway or gene. However, chronic inflammation is far more complex, involving an intricate web of signals and gene interactions.

Our breakthrough solution lies in four multimodal technology platforms capable of influencing hundreds of genes simultaneously. This innovation enables Filamon to design drugs that address chronic inflammation at its root, offering new hope for patients with conditions once considered intractable.

ALPHA

First-in-class inhibitors of epithelial-mesenchymal transition (EMT), a biological process that increases with age and is associated with increased risk of cancer and neuroinflammatory diseases.

Find Out More

BETA

First-in-class multi-modal angiogenic inhibitors based on inhibition of multiple genes including VEGF, ICAM-1, VCAM-1 and IL-6 involved in chronic inflammatory diseases of the eye.

Find Out More

LYTAP

First-in-class EGFR inhibitors based on targeted protein degradation by lysosomal proteolysis and relevant to cancer and a wide range of inflammatory diseases.

Find Out More

SIGMA

First-in-class inhibitors of enzymes involved in protein folding and displaying prion-like behaviour and believed to be associated with cancer and brain diseases.

Find Out More

Latest Company Presentations / News

Our Pipeline

Redefining Age-Related Disease Treatment with Next-Generation Anti-Inflammatory Drugs Targeting Complex Gene Networks

Kesonotide

Find Out More

BETA-002

Find Out More

LYTAP-001

Find Out More

ALPHA-003

Find Out More
Subscribe to receive
the latest news and updates
This field is for validation purposes and should be left unchanged.